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Abstract
Objectives: To assess the safety and tolerability as well as antiretroviral impact of aBX464, an oral investigational drug 
with a novel mechanism of hiV-1 inhibition (clinicalTrials.gov ncT02735863).
Methods: randomised, double-blind, placebo-controlled, Phase iia study in individuals living with hiV-1 on antiretroviral 
therapy at six clinical centres in spain, France and Belgium. aBX464 was administered once a day to 22 fully controlled 
hiV-1-positive participants at two doses (50 mg, n=6 and 150 mg, n=16) versus placebo, which was given to eight 
participants for 28 days in combination with a boosted protease inhibitor (darunavir/ritonavir or darunavir/cobicistat). 
The primary objective of the study was to assess aBX464 safety and tolerability when used in combination with darunavir 
boosted therapy. The secondary objective was to study antiretroviral efficacy on viral reservoirs using time to viral rebound 
following treatment interruption. The impact of aBX464 on hiV-1 reservoirs was further assessed by measuring levels 
of total hiV-1 in peripheral blood mononuclear cells (PBMcs) in the intervention arm versus placebo. a positive response 
was defined as an absolute reduction in hiV-1 Dna of at least 50 copies/106 PBMcs and a relative decrease >25% of 
hiV-1 Dna level.
Results: Twenty-six of the 30 randomly allocated participants completed the study according to the study protocol. 
aBX464 was found to be safe and well tolerated with the majority of adverse events (aes) being mild or moderate. Of 
the participants, 22 (73.3%) experienced treatment-associated aes (93.8%, 66.7%, 37.5% in the aBX464 150-mg, 
50-mg dose and placebo arms, respectively). Percentages for combined grade 3/4 aes for the three arms were 6.3%, 
0% and 12.5%, respectively.
Median time (Kaplan–Meier estimates) to viral rebound for aBX464 150-mg, 50-mg and placebo arms were 12.0 (95% 
confidence interval [ci]: 10–15), 15.5 (95% ci 14–22) and 15.5 (95% ci 1–22) days, respectively with no significant 
difference between the 150-mg treatment arm and placebo.
Median changes in total hiV-1 Dna copies/106 PBMcs for aBX464 150-mg, 50-mg and placebo arms after 28 days 
of treatment were −40 (range −434 to +194), −115 (range −116 to −114) and 25 (range −35 to +218), respectively, 
showing a decrease in the intervention arms. There were 6/14, 2/2, and 0/4 responders for aBX464 150 mg, 50 mg 
and placebo, respectively. no significant difference was seen between treatment arms and placebo with respect to these 
virological parameters.
Conclusions: This small controlled study confirmed the good safety and tolerability of aBX464 and provides some 
evidence of a potential reduction of the hiV-1 reservoir in terms of hiV-1 Dna levels in PBMcs when it was added to 
an hiV-1 protease inhibitor-based regimen. These results will need to be confirmed in a larger study.
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Introduction
Despite the major therapeutic success of antiretroviral therapy 
(arT) over the past decades, a functional (long-term control of 
hiV-1 in the absence of arT) or sterilising cure (elimination of 
all hiV-1-infected cells) still remains an elusive goal for the major-
ity of patients [1]. This is due to the persistence of reservoirs in 
some long-lived cell populations that harbour integrated latent 
hiV-1 provirus [2, 3]. although arT effectively suppresses hiV-
1-replication to undetectable levels in plasma, it cannot target 
integrated latent hiV-1 provirus in the absence of active replica-
tion. Therefore, arT, including hiV-1 protease, integrase and 
reverse transcriptase inhibitors, will require additional agents in 
order to achieve a cure [4].
aBX464 is a compound with a novel mechanism of viral inhibition 
as it promotes hiV-1 rna splicing events and interferes with the 
production of essential viral regulatory proteins such as rev and 
tat and inhibits viral mrna export required for gag, pol, env 
production and generation of genomic rna [5]. Both rna export 
and splicing are controlled by the cap-binding complex (cBc) 
that interacts directly with either rev or the transcription/export 
(TreX) complex, a multiprotein complex, required for transcrip-
tion and export of bulk mrnas [6]. aBX464, by binding directly 
to cBc, specifically prevents rev-mediated splicing and export 
of viral rna without interfering with cBc binding or cellular 
transcript export.
aBX464 has shown potent anti-hiV-1 activity in in vitro and in 
vivo preclinical studies [5]. it was highly effective in inhibiting 
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replication of different hiV-1 subtypes in PBMcs and macrophages 
and also substantially reduced virus replication in two humanised 
mouse models infected with hiV-1. Most significantly, there was 
a sustained reduction of viral load (Vl) levels in these mice after 
aBX464 treatment as compared to arT alone following treatment 
interruption [5].
a number of previous clinical studies that had enrolled a total 
of 72 healthy volunteers without hiV-1 and 50 individuals with 
hiV-1 have already confirmed aBX464 safety when given orally 
as monotherapy at doses up to 150 mg once a day (o.d.) [7–9]. 
in addition, an efficacy signal in terms of hiV-1 Vl reduction 
was described when aBX464 was given at higher doses, i.e. 100 
and 150 mg o.d. [9].
The present study was designed to further investigate aBX464 
safety, tolerability and antiretroviral efficacy when used in 
combination with arT such as boosted darunavir monother-
apy (darunavir/ritonavir [DrV/rTV] or darunavir/cobicistat 
[DrV/cOBi]).
Materials and methods
study design and participants
This was a placebo-controlled study aimed to assess the 
safety of aBX464, a novel antiretroviral agent, administered 
orally at the dose of 50 mg and 150 mg o.d. versus placebo 
in patients with hiV-1 on arT consisting of an hiV-1 boosted 
protease inhibitor such as 800 mg DrV with 100 mg rTV or 
800 mg DrV with 150 mg cOBi, for at least 8 weeks prior to 
baseline.
Participants needed to be fully suppressed (<50 hiV-1 copies/
ml) for at least 6 months prior to enrolment. at Day 0 of enrol-
ment into the study, aBX464 at either 50 mg or 150 mg o.d. or 
its matching placebo was added to this background therapy for 
the next 28 days.
a 3:1 randomisation ratio was applied per treatment block, i.e. 
three patients were to receive aBX464 on top of DrV/rTV or 
DrV/cOBi and one patient placebo on top of DrV/rTV or 
DrV/cOBi.
at Day 29, all treatment was to be discontinued. The hiV-1 viral 
load was monitored twice a week during the first 3 weeks of 
follow-up and weekly thereafter. in case of viral rebound (Vr) 
as defined below, arT was resumed.
Dose limiting toxicity (DlT) was defined as a grade 3 or higher 
adverse event using the ‘Division of aiDs Table for grading the 
severity of adult and Paediatric adverse events’ (version 2.0, 
2014) (including signs/symptoms, laboratory toxicities and/or 
clinical events) considered by the Data safety Monitoring Board 
as probably or definitely related to study treatment.
if more than two DlTs occurred during the treatment period of 
the first four treated participants, then the enrolment of additional 
patients was to be stopped. in addition, in case of a life-threatening 
(grade 4) adverse reaction, enrolment and treatment of ongoing 
patients was to be immediately discontinued. in both cases, enrol-
ment would only be resumed upon the decision of the sponsor 
if the Data safety Monitoring Board could conclude that the 
causality of the event was unrelated or unlikely to be related to 
the study treatment.
The primary outcome measures included the frequency of adverse 
reactions graded according to the ‘Division of aiDs table for 
grading the severity of adult and Paediatric adverse events’ 
(version 2.0 november 2014) (time frame: up to 4 months).
The secondary outcome measures included the time to Vr (time 
frame: up to 3 months). The time to Vr was defined as the time 
between treatment stop (i.e. Day 29) and Vr detection. We have 
further analysed hiV-1 reservoirs using total hiV-1 Dna/106 
PBMcs.
The main objective of the pharmacokinetic (PK) analysis was to 
evaluate the impact of concomitant administration of aBX464 
with boosted DrV (rTV/cOBi) and on aBX464 and its main 
metabolite nglc-aBX464 PK. considering that boosted DrV (rTV 
or cOBi) is a chronic treatment, it was deemed more relevant to 
evaluate the possible drug–drug interactions (DDi) at steady 
state and, as such, PK blood sampling was limited to the higher 
dosing interval.
The study was performed in one centre in France, two in spain and 
three in Belgium and conducted from May 2016 to august 2017. 
The clinical study (protocol no. aBX464-004), informed consent 
documents, and any other appropriate study-related documents 
were reviewed and approved by each clinical centre’s independent 
ethics committee/institutional review Board.
inclusion and exclusion criteria for enrolment and randomisation 
into the study are described in appendix 1.
randomisation and masking
Participants were randomly allocated at a 3:1 ratio to either an 
aBX464 or placebo arm at Day 0 if they fulfilled all inclusion 
criteria and none of the exclusion criteria. randomisation was 
centrally managed in blocks of four individuals (three aBX464, 
one placebo) and performed via the electronic case report form 
(ecrF). Vial numbers to be used for a specific participant were 
assigned according to a predefined randomisation list.
Procedures
all participants were treated with DrV/rTV or DrV/cOBi given 
as a monotherapy for at least 8 weeks prior to baseline. Boosted 
protease inhibitor treatment was given at the following doses: 
DrV 800 mg and rTV 100 mg o.d. with food or DrV 800 mg 
and cOBi 150 mg o.d. with food in the morning. The original 
fixed dose (i.e. aBX464 50 mg o.d.) of the study drug was selected 
based on the first safety data generated with this dose and of 
aBX464-n-glucuronide concentration, its active metabolite [7, 
8]. however, a first Phase iia study result conducted in treatment-
naïve individuals living with hiV-1 with high Vl upon enrolment 
demonstrated aBX464 antiretroviral activity at higher doses. a 
Vl reduction was observed in 3/12 participants in the aBX464 
75- and 100-mg cohorts and in 4/6 participants in the aBX464 
150-mg cohort, demonstrating a dose relationship effect of the 
drug [9]. Based on these findings it was decided to treat the 
first six participants with the 50 mg o.d. dose. after 28 days of 
treatment the safety data would be reviewed by the Data safety 
Monitoring Board (DsMB) and in the event of no participants 
demonstrating a DlT, the study would enrol another 16 partici-
pants on aBX464 150-mg o.d. dose. The DsMB was convened 
after every four participants on aBX464 150 mg o.d. were recruited 
in order to review safety and to recommend, if appropriate, the 
continuation of the study.
Following participant screening, eligible individuals continued 
DrV/rTV or DrV/cOBi o.d. with food in the morning. at Day 
0, the study drug, i.e aBX464 or its matching placebo was added 
to background therapy for the next 28 days, at the fixed dose 
at breakfast of 50 mg (1×50-mg capsule) or 150 mg (3×50-mg 
capsules) o.d.
The initial study screening visit was carried out 21 ± 7 days prior 
to first dosing and individuals who met all the inclusion criteria 
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and none of the exclusion criteria were eligible for inclusion into 
the study and a randomisation visit on the day of first study 
drug distribution (Day 0). During this visit, samples were drawn 
for serology (hiV, hBV and hcV), hiV-1 viral load and cD4/
cD8 count. The randomisation visit was carried out on Day 0 
with blood sampling. subsequent visits were carried out on Day 
7, 14, 21 and 28 ± 2 days and at Day 25 ± 4 (for PK measure-
ments). The schedule and full list of laboratory tests and safety 
evaluations carried out for each visit are described in appendix 2.
The treatment phase was terminated at the Day-28 visit with 
all treatment being interrupted. in this open-ended study, study 
visits were then performed initially twice weekly and then once 
weekly during the treatment interruption period until Vr and 
reintroduction of arT. Viral rebound was defined as a single 
measurement of hiV-1 Vl >1000 copies/ml plasma. arT rein-
troduction was performed according to the participant’s medical 
and arT history with the aim of achieving undetectable Vl. The 
participant with Vr was withdrawn from the study and follow-up 
visits were carried out every 14 days until the Vl had returned 
to undetectable levels. The last follow up was considered the 
end of study visits. in the event of an absence of Vr, then the 
end of the study was designated to be 3 months after treatment 
interruption.
Prior to the statistical analyses, adverse events (aes) were coded 
using the MedDra dictionary in order to be tabulated by system 
organ class (sOc) and preferred term (PT). The number of par-
ticipants (n[%]) with at least one treatment-emergent ae (Teae) 
was tabulated by sOc and PT for each group and dose. The 
number of Teaes was also analysed in the same way, by sOc 
and PT for each group and dose, by grade of severity for each 
group and dose, and by level of causality to the study drug for 
each group and dose.
Total hiV-1 Dna was quantified in participants on Day 0 and 
Day 28 of study drug plus background therapy by droplet digital 
Pcr (ddPcr). Briefly, blood was drawn and PBMcs were isolated. 
Total genomic hiV-1 Dna was isolated from 107 cells and prior 
to Pcr amplification, an enzyme restriction digestion with ecori 
(Promega, leiden, the netherlands) was performed. The ddPcr 
reaction mix consisted of 10 μl 2×ddPcr supermix for probes 
(Bio-rad), 500 nM of primers and 300 nM of probe in a final 
volume of 20 μl (sequences of assay described in schvachsa et 
al, [10]). Following amplification, droplets were read by the QX200 
droplet reader (Bio-rad) and data were analysed with the ddp-
crquant analysis software [11]. Participants with <5 droplets in 
three replicates at the two time-points (days 0, 28) were excluded 
from the analysis, as it was considered that measurements of 
such low Dna content could be inaccurate.
since PK analysis was performed at steady-state, PK blood sam-
pling was limited to the higher dosing interval. a first blood 
sample (reference) for boosted DrV (rTV or cOBi) was collected 
on the first day of treatment before any drug administration. 
Blood samples were then collected for PK purpose at Days 0, 
7, 14 and 21, before the boosted DrV (rTV or cOBi) morning 
dose and at Day 25, before the boosted DrV (rTV or cOBi) 
morning dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, and 
24 h post-dose. The following PK parameters were derived for 
aBX464, aBX464-nglc, boosted DrV (rTV or cOBi) on Day 25 
for each patient: cmax and the time taken to reach cmax (tmax) were 
obtained directly from the concentration-time data; aUc0-t (24 h 
post-dose for aBX464 and aBX464-nglc, and 12 h post-dose 
for DrV (rTV and cOBi). if no concentration could be measured 
at this time-point, area under the plasma concentration-versus-
time curve from time zero to the time of the last quantifiable 
concentration (aUc0-last) was calculated. Plasma samples were 
analysed using validated bioanalytical methods by atlanbio (saint 
nazaire, France) according to good laboratory practice. aBX464 
and its metabolite aBX464-nglc, DrV, rTV and cOBi plasma phar-
macokinetic parameters were assessed using a non-compartmental 
method by Winnonlin (version 6.4) software.
Outcomes
The primary objective of the study was to evaluate the safety 
and tolerability of aBX464 versus placebo when administered 
in combination with DrV/rTV or DrV/cOBi. The second-
ary objectives were: (i) to evaluate the longer-lasting effect of 
aBX464 versus placebo on Vl after treatment interruption on 
Day 29 using time to Vr; (ii) to compare the effect of aBX464 
versus placebo on Vl from Day 0 to the time of Vr; (iii) to 
compare the effect of aBX464 versus placebo on the cD4 T 
cell count from Day 0 to the time of Vr; (iv) to compare the 
effect of aBX464 versus placebo on the cD4/cD8 T cell ratio 
from Day 0 to the time of Vr; (v) to evaluate the effect of 
aBX464 versus placebo on the hiV-1 reservoir (total hiV-1 Dna 
in PBMcss) from Day 0 to Vr; and (vi) to evaluate the impact 
of concomitant administration of boosted DrV on aBX464 
pharmacokinetics.
statistical analysis
The sample size selection was based on a virological efficacy 
endpoint although safety was the primary endpoint. The endpoint 
chosen for the sample size calculation was the time to Vr defined 
as the time between treatment stop (i.e. Day 29) and Vr detec-
tion. according to published studies [12], the expected median 
time to Vr (calculated from treatment stop) was expected to be 
7 days in the DrV/rTV or cOBi and placebo arm and at least 
28 days in the DrV/rTV or cOBi and aBX464 arm. The power 
to detect a difference between the intervention arms and placebo 
was calculated using the PrOc POWer (sas software, version 
9.4). Thus, the enrolment of 28 evaluable participants (21 in the 
aBX464 arm at 50 mg or 150 mg o.d. and seven in the placebo 
arm) would allow an 80% chance to detect a significant differ-
ence at the P=0.05 level, between arms.
all efficacy analyses were conducted on both the full-analysis 
dataset population and the per-protocol dataset population, except 
if otherwise specified. Descriptive statistics are presented by 
treatment arm and include quantitative variables: mean, standard 
deviation, minimum and maximum, 95% confidence intervals.
The statistical study plan was finalised before study unblinding 
and analysis. it defined the following criteria: (i) only participants 
with >50 copies of total hiV-1 Dna/106 PBMcs at baseline were 
considered evaluable (this was related to the lower limit of quan-
tification of the Pcr assay as a decrease from a baseline of ≤50 
copies/106 PBMcs would have been inappropriate for interpreta-
tion); and (ii) participants who showed a relative reduction of 
total hiV-1 Dna/106 PBMcs between Day 0 and Day 28 of at 
least 25% and an absolute reduction of at least 50 hiV-1 
copies/106 PBMcs were defined as responders.
Results
Baseline demographic characteristics and  
participant disposition
The study was conducted in Belgium, spain and France. a total 
of 35 participants were enrolled into the study, of whom 30 
were randomly allocated to one of three arms. Their demographic 
characteristics are described in Table 1. These varied slightly across 
treatment arms; however, they were not considered clinically 
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Table 1. Demographic and baseline participant characteristics
50 mg ABX464
(n=6)
150 mg ABX464
(n=16)
Placebo
(n=8)
Age (years) Mean (sD)
Median [range]
45.2 (3.5)
45.5 [41–49]
38.4 (10.4)
38.0 [21–60]
48.3 (8.5)
50.0 [34–56]
Sex Male
Female
6 (100.0%)
0
15 (93.8%)
1 (6.3%)
8 (100.0%)
0
Ethnicity White
asian
Black
Other
6 (100.0%)
0
0
0
14 (87.5%)
0
2 (12.5%)
0
7 (87.5%)
1 (12.5%)
0
0
Height (cm) Mean sD
Median [range]
170.5 (6.7)
170.5 [160–180]
175.9 (7.6)
176.0 [164–190]
174.3 (8.4)
175.0 [165–184]
Weight (kg) Mean sD
Median [range]
73.00 (10.64)
73.50 [59.0–89.0]
79.88 (18.92)
71.00 [58.0–115.0]
76.25 (12.34)
73.00 [61.0–94.0]
BMI (kg/m2) Mean sD
Median [range]
25.10 (3.23)
25.10 [19.9–29.4]
25.80 (5.95)
23.55 [20.4–41.5]
24.98 (2.22)
25.20 [21.5–28.1]
CD4 cell count (cells/mm3) Mean (sD)
Median [range]
1004 (201)
982 [800–1340]
926 (394)
784 [426–1792]
698 (179)
681 [448–998]
Plasma HIV-1 viral load 
(copies/mL)
Mean (sD)
Median [range]
29.2 (11.1)
29.0 [19–40]
96.1 (275.9)
19.0 [19–1130]
29.1 (10.8)
29.0 [19–40]
n: number of participants; sD: standard deviation; BMi: body mass index.
n=2
Early
withdrawal
Lost to follow-up (n=1) Investigator decision (n=1)
Investigator decision (n=1)
AE (n=1)
n=6
50 mg ABX464
n=16
150 mg ABX464
n=8
Placebo
n=30
Randomised
n=35
Enrolled
n=5
Screening
failures
- Inclusion criterion not met (n=2)
- Exclusion criterion (n=1)
- Withdrawal by patient (n=1)
- Other reason (n=1)
n=1
Early
withdrawal
n=5
Completed
n=14
Completed
n=1
Early
withdrawal
n=7
Completed
Figure 1. study participant disposition. n: number of participants
relevant. The study population had a median age of 38, 45.5 
and 50 years and a cD4 T cell count of 784, 982 and 681 cells/
mm3 in the 150-mg, 50-mg and placebo arms, respectively.
From among the 30 participants, six were randomly allocated to 
the aBX464 50-mg, 16 to the aBX464 150-mg dose and eight 
to the placebo (Figure 1). Twenty-six participants completed the 
study according to the study protocol: five from the aBX464 
50-mg arm, 14 from the aBX464 150-mg arm and seven from 
the placebo arm. Four participants withdrew early from the study 
(one from the aBX464 50-mg arm, two from the aBX464 150-mg 
arm and one from the placebo arm). The reasons for withdrawal 
were investigators’ decision (two participants), ae (one partici-
pant), lost to follow-up (one participant).
Safety and tolerability
Overall, a total of 128 adverse events (aes) were experienced by 
27/30 participants (90%). among these, 81 were classified as 
treatment emergent (Teaes) (22/30 participants; 73·3%), 36 
as post-Teaes (14/30 participants; 46·7%). eleven pretreatment 
events were reported. Of the 22 participants who experienced 
Teaes, the highest frequency was observed in the aBX464 150-mg 
arm (15/16 participants experienced 58 aes), followed by the 
aBX464 50-mg arm (4/6 participants experienced 10 aes) 
and placebo arm (3/8 participants experienced 13 events). The 
frequency and severity of the most frequent Teaes, by system 
order class (sOc), regardless of their relationship with the study 
treatment, are presented in Table 2. a full listing of all Teaes by 
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Table 2. summary of treatment-emergent adverse events, by system organ class and severity according to treatment allocation
System organ class Severity ABX464 50 mg
Total=6
ABX464 150 mg
Total=16
Placebo
Total=8
TEAEs
n
Participants
na (%)
TEAEs
n
Participants
na (%)
TEAEs
n
Participants
na (%)
any treatment-emergent 
adverse events
all 10 4 (66.7) 58 15 (93.8) 13 3 (37.5)
Mild 9 3 (50.0) 38 6 (37.5) 11 2 (25.0)
Moderate 1 1 (16.7) 19 8 (50.0) 2 1 (12.5)
severe 0 0 (0.0) 1 1 (6.3) 0 0 (0.0)
Blood and lymphatic system 
disorders
all 2 1 (16.7) 0 0 (0.0) 0 0 (0.0)
Mild 2 1 (16.7) 0 0 (0.0) 0 0 (0.0)
Moderate 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
severe 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
gastrointestinal disorders all 2 1 (16.7) 23 13 (81.3) 1 1 (12.5)
Mild 2 1 (16.7) 16 7 (43.8) 1 1 (12.5)
Moderate 0 0 (0.0) 7 6 (37.5) 0 0 (0.0)
severe 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
general disorders and 
administration site conditions
all 2 1 (16.7) 10 6 (37.5) 1 1 (12.5)
Mild 1 0 (0.0) 4 3 (18.8) 1 1 (12.5)
Moderate 1 1 (16.7) 5 2 (12.5) 0 0 (0.0)
severe 0 0 (0.0) 1 1 (6.3) 0 0 (0.0)
infections and infestations all 0 0 (0.0) 3 3 (18.8) 7 3 (37.5)
Mild 0 0 (0.0) 2 2 (12.5) 5 2 (25.0)
Moderate 0 0 (0.0) 1 1 (6.3) 2 1 (12.5)
severe 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
injury, poisoning and 
procedural complications
all 2 2 (33.3) 0 0 (0.0) 0 0 (0.0)
Mild 2 2 (33.3) 0 0 (0.0) 0 0 (0.0)
Moderate 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
severe 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
investigations all 0 0 (0.0) 2 2 (12.5) 1 1 (12.5)
Mild 0 0 (0.0) 1 1 (6.3) 1 1 (12.5)
Moderate 0 0 (0.0) 1 1 (6.3) 0 0 (0.0)
severe 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
Metabolism and nutrition 
disorders
all 0 0 (0.0) 1 1 (6.3) 0 0 (0.0)
Mild 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
Moderate 0 0 (0.0) 1 1 (6.3) 0 0 (0.0)
severe 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
Musculoskeletal and 
connective tissue disorders
all 0 0 (0.0) 10 8 (50.0) 2 2 (25.0)
Mild 0 0 (0.0) 7 5 (31.3) 2 2 (25.0)
Moderate 0 0 (0.0) 3 3 (18.8) 0 0 (0.0)
severe 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
nervous system disorders all 2 2 (33.3) 7 5 (31.3) 0 0 (0.0)
Mild 2 2 (33.3) 6 4 (25.0) 0 0 (0.0)
Moderate 0 0 (0.0) 1 1 (6.3) 0 0 (0.0)
severe 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
Psychiatric disorders all 0 0 (0.0) 1 1 (6.3) 0 0 (0.0)
Mild 0 0 (0.0) 1 1 (6.3) 0 0 (0.0)
Moderate 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
severe 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
renal and urinary disorders all 0 0 (0.0) 1 1 (6.3) 0 0 (0.0)
Mild 0 0 (0.0) 1 1 (6.3) 0 0 (0.0)
Moderate 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
severe 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
skin and subcutaneous 
tissue disorders
all 0 0 (0.0) 0 0 (0.0) 1 1 (12.5)
Mild 0 0 (0.0) 0 0 (0.0) 1 1 (12.5)
Moderate 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
severe 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
a if a subject experienced multiple adverse events categorised under the same system organ class, this subject is shown only once within the highest severity 
grading. n: number of participants
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Table 3. Time to hiV-1 viral load rebound (full data analysis set)
50 mg ABX464
(n=6)
150 mg ABX464
(n=16)
Placebo
(n=8)
P value
Time to viral load rebound (days) Mean (sD)
Median [range]
17.2 (3.4)
15.5 [14–22]
14.4 (7.4)
11.5 [8–39]
14.4 (7.3)
15.5 [1–23]
Kaplan–Meier estimate (days) Median (95% ci) 15.5 (14.0–22.0) 12.0 (10.0–15.0) 15.5 (1.0–22.0)
Log-rank test 0.5352
n: number of participants; sD: standard deviation; ci: confidence interval.
The log-rank test analysis was conducted for aBX464 150 mg and placebo only.
Table 4. changes in total hiV-1 Dna
50 mg ABX464
(n=2)
150 mg ABX464
(n=14)
Pooled ABX464 arms
(n=16)
Placebo
(n=4)
Day 0 (copies/million 
PBMCs)
Mean (sD)
Median [range]
300.0 (21.2)
300.0 [285–315]
444.6 (289.5)
393.0 [72–961]
426.6 (274.1)
352.5 [72–961]
183.0 (85.4)
163.5 [112–293]
Day 28 (copies/million 
PBMCs)
Mean (sD)
Median [range]
185.0 (22.6)
185.0 [169–201]
398.9 (226.6)
388.5 [77–734]
372.1 (223.3)
325.0 [77–734]
241.3 (204.2)
188.5 [77–511]
Change between day 0 
and day 28 (copies/
million PBMCs)
Mean (sD)
Median [range]
-115.00 (1.41)
-115.00 [-116.0–114.0]
-45.79 (181.75)
-40.00 [-434.0–194.0]
-54.44 (170.84)
-84.50 [-434.0–194.0]
58.25 (118.99)
25.00 [-35.0–218.0]
n: number of participants; sD: standard deviation.
preferred term is provided in appendix 3. The majority were graded 
as mild (grade 1) or moderate (grade 2); one Teae was graded 
as severe (grade 3), i.e. a participant in the aBX464 150-mg 
arm suffered from severe fatigue. One serious ae (vagal faint-
ness) was reported for a participant allocated to the placebo arm.
The majority of Teaes were considered by the investigators as 
not related to the aBX464 study drug. Of 81 Teaes reported, 
18 were considered aBX464 drug–related and were present in 
8/16 participants in the aBX464 150-mg arm with none being 
present in the 50-mg arm. Two Teaes led to the investigational 
study drug discontinuation in one participant in the aBX464 
150-mg arm. The individual presented with abdominal pain (grade 
2; unrelated to aBX464) and upper abdominal pain (grade 1; 
unrelated to aBX464), both of which started on study Day 1 
and resolved 16 days later.
The most frequently reported Teaes by sOc were gastrointestinal 
(50%), musculoskeletal and connective tissue disorders (33.3%), 
general disorders and administration site conditions (26.7%) and 
central nervous system disorders (23.3%) (Table 2). The Teaes by 
PT that occurred in over 10% of participants across treatment arms 
included headache, back pain, upper abdominal pain, diarrhoea, 
abdominal pain, nausea, fatigue and arthralgia (appendix 3).
cD4 T cell count and cD4/cD8 T cell ratio analysis
The cD4 T cell count and cD4/cD8 T cell ratio were assessed 
at all visits during the treatment period (Days 0, 7, 14, 21, 25 
and 28), then, twice a week during the first 3 weeks after treat-
ment interruption, and once a week thereafter until Vr detection. 
no significant difference was seen between the aBX464 150-mg 
and placebo arms for these markers. The cD4 T cell count and 
cD4/cD8 T cell ratio are summarised in appendices 4 and 5, 
respectively.
efficacy
The main efficacy endpoint was the time (days) to Vr defined 
as the time between the end of treatment (Day 29) and Vr 
detection (viral load >1000 copies/ml). results for the full analysis 
set for the three arms are summarised in Table 3.
Median time to Vr (Kaplan–Meier estimate) was 15.5 days (95% 
ci 14.0–22.0) for the aBX464 50-mg arm, 12.0 days (95% ci 
10·0–15·0) for the aBX464 150-mg arms and 15.5 days (95% 
ci 1·0–22·0) for the placebo arm. Kaplan–Meier plots for the 
three treatment arms for time to Vr are shown in appendix 6. 
log-rank test analysis showed no significant difference between 
the aBX464 150-mg and placebo arms (P=0·5352).
in addition, the impact of aBiVaX464 on hiV-1 reservoirs was 
investigated by assessing total hiV-1 Dna (copies/106 PBMcs) 
at Day 0 and 28 post-randomisation and were descriptively sum-
marised by aBX464 dose and pooled doses (50 mg and 150 mg). 
The mean change in absolute total hiV-1 Dna levels from Day 
0 to Day 28 is also summarised for the per-protocol set, by dose 
and pooled doses (Table 4). a number of individuals were excluded 
from the per-protocol analysis set because of consistently low 
hiV-1 reservoirs (<5 droplets) at both time-points (days 0 and 
28), which prevented reliable conclusions on reservoir changes 
(see Methods). The data showed a potential impact of aBX464 
on reservoirs with a median reduction in total hiV-1 Dna from 
Day 0 to Day 28 at the 50-mg dose (-115·00 copies/106 PBMcs; 
range −116 to −114) and at the 150-mg dose (–40.00 copies/106 
PBMcs; range −434 to +194), while an increased level was noted 
in the placebo arm (+25.00 copies/106 PBMcs; range −35 to 
+218). The number (%) of responders for the per-protocol set 
who had a decrease in total hiV-1 Dna after aBX464 treatment 
are summarised in Table 5. This analysis confirmed the antiviral 
signal seen in terms of decrease in hiV-1 Dna copy number in 
PBMcs in aBX464-treated participants with a higher proportion 
of responders in the aBX464 150-mg (6/14 participants; 42·9%) 
and aBX464 50-mg arms (2/2 participants, 100%) in comparison 
to the placebo arm (0/4 participants, 0%) at Day 28. however, 
the difference in percentage of responders between the aBX464 
150-mg and placebo arms was not significant (Fisher’s exact 
test) (P=0.2451).
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Table 5. Total hiV-1 Dna analysis
50 mg 
ABX464
150 mg 
ABX464
Placebo Difference in proportion*
(95% CI)
Fisher’s exact test
P value
All evaluable participants 
at day 28
n=2 n=14 n=4
responder 2 (100.0%) 6 (42.9%) 0
non-responder 0 8 (57.1%) 4 (100.0%)
42.9% (-10.6–67.4) 0.2451
n: number of participants; ci: confidence interval.
*Difference in proportion is calculated for aBX464 150 mg versus placebo
Pharmacokinetics
Data showed that in most subjects, regardless of the dose, no 
aBX464 plasma concentrations could be detected after 8–12 h 
post-dose. cmax was generally observed within the first 2 h post-
dose. after repeated oral administration of 50 and 150 mg 
aBX464, the drug was extensively biotransformed into its n-glu-
curonide metabolite, aBX464-nglc. The metabolite plasma con-
centrations were higher than those of the parent drug with mean 
cmax about 40–54-fold higher than aBX464 cmax; cmax was observed 
around 4 h post-dose. For cOBi, mean cmax and mean aUclast 
(obtained at mean Tlast around 18 hours, 24 hours and 22 hours, 
respectively) were similar after repeated administration of placebo 
or after 50 or 150 mg aBX464 repeated administration. Mean 
cmax and mean aUclast (obtained at mean Tlast around 24 hours) 
was similar for DrV after repeated administration of placebo or 
after the 50 or 150 mg aBX464 repeated administration. however 
for rTV, after 50 mg aBX464 repeated administration, mean cmax 
and mean aUclast (obtained at mean Tlast around 24 hours) were 
about two times lower than after placebo or after 150 mg aBX464 
repeated administration.
Discussion
This study confirms previous findings from published trials showing 
that aBX464, a novel antiretroviral investigational drug, has a 
good safety and tolerability profile in individuals living with hiV-1 
and is the first to use aBX464 in combination with arT (i.e. 
boosted DrV monotherapy). Treatment simplification with DrV-
boosted monotherapy is reported to be safe and effective in 
routine clinical practice and was deemed relevant with respect 
to the study design and objectives [13].
a comparison of the aes in this study with previous studies, 
where aBX464 was used as monotherapy, did not show an inferior 
safety or tolerability profile when combined with a boosted hiV 
protease inhibitor.
Unlike in previous studies, vomiting was not recorded whereas 
up to 67% of individuals treated with the aBX464 150-mg dose 
suffered mild or moderate vomiting in a previous aBX464 mono-
therapy study [9]. in addition, the incidence of headache was 
lower in this study with 5/16 participants (31.3%) in the 150-mg 
group reporting mild or moderate events compared to 66.7–100% 
in the monotherapy study. however, fatigue and back pain, which 
had not been reported in previous studies, were present in a 
number of participants receiving the aBX464 150-mg dose.
The analysis carried out in this study also demonstrated that key 
PK parameters such as aBX464 mean cmax and mean aUclast were 
similar in individuals after aBX464 repeated administration com-
bined with boosted DrV (rTV or cOBi) to those obtained in 
previously arT-naïve hiV-1-positive individuals [9]. however, 
the main aBX464 metabolite nglc-aBX464 mean cmax and aUclast 
were approximately 5- and 17-times lower, respectively after 
aBX464 repeated administration in participants receiving com-
bined therapy as compared to previous results in untreated hiV-
1-positive individuals [9]. Therefore, the impact of arT on aBX464 
pharmacokinetics will need to be fully investigated in future 
studies. The co-administration of aBX464 with DrV/rTV or DrV/
cOBi did not appear to impact the PK characteristics of these 
drugs. Mean cmax and mean aUclast were similar after repeated 
administration of placebo or after aBX464 repeated administra-
tion and the measured PK characteristics were in agreement with 
published data [14,15]. The only difference was seen for rTV: 
mean cmax and mean aUclast were similar after repeated admin-
istration of placebo or after 150 mg aBX464 repeated adminis-
tration and were in agreement with published data [14]. however; 
after 50 mg aBX464 repeated administration, mean cmax and 
mean aUclast were approximately two times lower than after placebo 
or after 150 mg aBX464 repeated administration. These results 
have to be viewed with caution due to the low number of subjects 
and the fact that no differences were seen with the higher 150-mg 
aBX464 dose.
Previous data in treatment-naïve hiV-1-positive individuals had 
detected a dose-dependent efficacy signal with respect to plasma 
Vl reduction following a 14-day aBX464 treatment period [9]. 
The present study was therefore designed to potentially enhance 
this effect by combining aBX464 with a boosted hiV-1 protease 
inhibitor, and to evaluate Vr after treatment interruption. The 
primary efficacy variable for statistical comparison between treat-
ment arms was the time to Vr (days). The present data demon-
strated no significant difference by Kaplan–Meier estimates 
between the aBX464 150-mg and placebo arms.
although total hiV-1 Dna overestimates the size of the repli-
cation-competent hiV-1 reservoir [16], it has been shown to be 
more predictive of disease progression than plasma Vl and, of 
time to Vr post-treatment interruption [17]. a reduction in the 
reservoir size may prolong time to Vr [18, 19].
an aBX464-mediated antiviral signal was demonstrated with 
a median decrease in total hiV-1 Dna of 40 copies per 106 
PBMcs in the aBX464 150-mg treatment arm as compared to 
an increase of 25 copies in the placebo group. in addition, there 
were no responders (0/4) in the placebo arm, 2/2 in the aBX464 
50-mg and 6/14 (42.9%) in the aBX464 150-mg treatment 
arms when using our study criteria for responders. These results 
are encouraging in view of the failure of multiple interventions 
to achieve a measurable reduction of the hiV-1 reservoir size 
in other randomised studies. a novel antiviral agent that blocks 
hiV Vpu ion channel activity [20] had a 63% reduction in the 
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mean total hiV-1 Dna copy number in monocytes of treated 
individuals.
Our study failed to demonstrate a significant difference in time 
to Vr in aBX464-treated individuals following treatment inter-
ruption. This was, however, in contrast to data obtained in pre-
clinical humanised mouse studies, where hiV-1-infected nOg 
hu mice were treated with aBX464 for 4 weeks [5]. These studies 
had shown a substantial reduction in Vr over the 52-day obser-
vation period after aBX464 treatment interruption. The reasons 
for the discrepancy are unclear. The duration of 28 days of aBX464 
may have been insufficient to sufficiently reduce the reservoir 
load and consequently no delay in Vr was observed. a longer 
treatment period with aBX464 may be needed in order to evalu-
ate its potential full impact on the hiV-1 reservoir as well as a 
larger number of participants.
in conclusion, as in previous studies with aBX464 monotherapy 
[7–9], we have shown that aBX464 was safe and well tolerated 
in fully suppressed hiV-1-positive individuals on boosted DrV. 
an efficacy signal was observed in the aBX464-treated group 
with respect to a reduction of total hiV-1 Dna in PBMcs. but 
this was not associated with a delay in the time to Vr after 
therapy interruption.
a second Phase iia study is currently ongoing using aBX464 for 
a longer treatment period (84 days) in addition to triple therapy 
and will include a more extensive analysis of integrated hiV-1 
Dna performed to evaluate the impact of aBX464 on the hiV-1 
reservoir in blood and gut tissue.
Acknowledgements
The work was funded by aBiVaX.
aBiVaX employees were involved in the study design, data col-
lection, analysis and interpretation, writing of the report and the 
decision to submit for publication.
The study design was provided by JMs, Pg, JT, Ds, hJe and lV. 
study analyses and manuscript writing were provided by PnB, 
Pg, JMs, JT, sr and lV. nucleic acid analyses were carried out 
by sr, Bc and sK.
JMs, Pg, Ds and hJe are aBiVaX employees and hold aBiVaX 
stock options. PnB performs consultancy services for aBiVaX. 
lV was investigator of the study and received consultancy fees. 
JT is a member of a collaborative laboratory that has received 
financial support from aBiVaX.
The authors thank all the study participants for their commitment 
and all personnel at the different clinical centres who took part 
in this study.
References
1. Margolis DM. Towards an hiV cure: a view of a developing field. J Infect Dis 2017; 
215 Suppl 3: s109–s110.
2. lee gQ, lichterfeld M. Diversity of hiV-1 reservoirs in cD4+ T-cell subpopulations. 
Curr Opin HIV AIDS 2016; 11: 383–387.
3. Wong JK, Yukl sa. Tissue reservoirs of hiV. Curr Opin HIV AIDS 2016; 11: 362–370
4. Margolis DM, garcia JV, hazuda DJ, haynes BF. latency reversal and viral clearance 
to cure hiV-1. Science 2016; 353: aaf6517.
5. campos n, Myburgh r, garcel a et al. long lasting control of viral rebound with 
a new drug aBX464 targeting rev-mediated viral rna biogenesis. Retrovirology 
2015; 12: 1–15.
6. Tazi J, Bakkour n, Marchand V et al. alternative splicing: regulation of hiV-1 
multiplication as a target for therapeutic action. FEBS J 2010; 277: 867–876.
7. scherrer D, rouzier r, Barrett Pn, et al. Pharmacokinetics and tolerability of aBX464, 
a novel first-in-class compound to treat hiV infection, in healthy hiV-uninfected 
subjects. J Antimicrob Chemother 2017; 72: 820–828.
8. scherrer D, rouzier r, cardona M et al. randomized trial of food effect on phar-
macokinetic parameters of aBX464 administered orally to healthy male subjects. 
Antimicrob Agents Chemother 2017; 61: e01288–16.
9. steens JM, scherrer D, gineste P et al. safety, pharmacokinetics and antiviral 
activity of a novel hiV antiviral, aBX464, in treatment-naïve hiV infected subjects: 
a Phase ii randomized, controlled study. Antimicrob Agents Chemother 2017; 61: 
e00545–17.
10. schvachsa n, Turk g, Burgard M et al. examination of real-time Pcr for hiV-1 rna 
and Dna quantitation in patients infected with hiV-1 BF intersubtype recombinant 
variants. J Virol Methods 2007; 140: 222–227.
11. Trypsteen W, Vynck M, De neve J et al. ddpcrquant: threshold determination for 
single channel droplet digital Pcr experiments. Anal Bioanal Chem 2015; 407: 
5827–5834.
12. el Bouzidi K, collier D, nastouli e et al. Virological efficacy of Pi monotherapy for 
hiV-1 in clinical practice. J Antimicrob Chemother 2016; 71: 3228–3234.
13. arribas Jr, girard PM, Paton n et al. efficacy of protease inhibitor monotherapy 
vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized 
trials. HIV Med 2016; 17: 358–367.
14. King Jr, Khatri a, Trinh r et al. Pharmacokinetics of darunavir, ombitasvir, pari-
taprevir, ritonavir, dasabuvir and ribavirin in adults infected with hepatitis c virus 
genotype 1 and human immunodeficiency virus (hiV). 17th International Workshop 
on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington Dc, Usa. June 
2016. abstract O_20.
15. Kakuda Tn, Van De casteele T, Petrovic r et al. Bioequivalence of a darunavir/
cobicistat fixed-dose combination tablet versus single agents and food effect in 
healthy volunteers. Antivir Ther 2014; 19: 597–606.
16. rouzioux c, avettand-Fenoël V. Total hiV Dna: a global marker of hiV persistence. 
Retrovirology 2018; 15: 30.
17. Williams JP, hurst J, stöhr W et al; sParTac Trial investigators. hiV-1 Dna predicts 
disease progression and post-treatment virological control. eLife 2014; 3: e03821.
18. Pinkevych M, cromer D, Tolstrup M et al. hiV reactivation from latency after 
treatment interruption occurs on average every 5–8 days. implications for hiV 
remission. PLoS Pathog 2015; 11: e1005000.
19. Barton K, Winckelmann a, Palmer s. hiV-1 reservoirs during suppressive therapy. 
Trends Microbiol 2016; 24: 345–355.
20. Wilkinson J, ewart g, luscombe c et al. a Phase 1b/2a study of the safety, 
pharmacokinetics and antiviral activity of BiT225 in patients with hiV-1 infection. 
J Antimicrob Chemother 2016; 71: 731–738.
Appendix 1. Study inclusion and  
exclusion criteria
Inclusion criteria
a participant was eligible for inclusion into this study only if all 
of the following criteria applied:
• Participants living with hiV-1;
• Participants with hiV plasma viral load ≤50 copies/ml during 
the 6 months prior to screening with a maximum of two blips 
(increases above 50 copies/ml) during this period;
• Participants treated with darunavir/ritonavir (DrV/r) or daru-
navir/cobicistat (DrV/c) as a monotherapy for at least 8 weeks 
prior to baseline;
• Participants’ hiV plasma viral load ≤100,000 copies/ml at 
any time (apart from primary infection if recorded);
• Participants’ cD4 T cell count ≥250 cells/mm3 at any time 
since diagnosis;
• Participants with cD4 T cells count ≥600 cells/mm3 at 
screening;
• Man or woman aged 18–65 years;
• haematological and biochemical laboratory parameters as 
follows and within 7 days of baseline:
○ haemoglobin >9·0 g/100 ml
○ absolute neutrophil count ≥750/mm3;
○ Platelets ≥100,000/μl
○ Total serum creatinine ≤1·3×upper limit of normal (Uln);
○ creatinine clearance >50 ml/per min using the cockcroft-
gault equation within 60 days of entry;
○ Total serum bilirubin <1.5×Uln;
○ alkaline phosphatase, alanine aminotransferase (asT), serum 
glutamic pyruvate transaminase (sgOT) and alanine amino-
transferase (alT), serum glutamic pyruvate transaminase 
(sgPT) <1·5×Uln;
○ serum lipase ≤2·0×Uln;
• Participants should have been able and willing to comply with 
study visits and procedures as per protocol;
• Participants should have understood, signed and dated the 
written informed consent form at the screening visit prior to 
any protocol-specific procedures being performed;
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• Participants should have been affiliated to a social security 
regimen (for French sites only); and
• Females and males receiving the study treatment and their 
partners must have agreed to use a highly effective contra-
ceptive method during the study period and for 3 months 
after the end of the study period or early termination. con-
traception should have been in place at least 2 weeks prior 
to study participation. Women must be surgically sterile or, if 
of childbearing potential, must have used a highly effective 
contraceptive method. Women of childbearing potential entered 
the study after confirmed menstrual periods and a negative 
pregnancy test. highly effective methods of contraception 
included true abstinence, intrauterine device (iUD) or hor-
monal contraception associated with inhibition of ovulation, 
intrauterine hormone releasing system, bilateral tubal occlu-
sion, vasectomised partner. True abstinence was defined when 
this was in line with the preferred and usual lifestyle of the 
participant. in each case of delayed menstrual period (over 
1 month between menstruations) confirmation of absence of 
pregnancy was required. This recommendation also applied to 
women of childbearing potential with infrequent or irregular 
menstrual cycle.
Exclusion criteria
The following criteria were checked at the time of screening. if 
anY exclusion criterion applied, the participant could not be 
included into the study:
• Participant displaying any hiV protease inhibitor resistance 
mutation as listed in the current version of the hiV drug 
resistance database (stanford University);
• Participant having had previously an hiV viral load ≥500 
copies/ml confirmed by a second measure since the initiation 
of the current antiretroviral therapies (arT);
• history of an acquired immune deficiency syndrome (aiDs)-
defining clinical illness;
• concomitant aiDs-related opportunistic disease;
• history of allergic disease, anaphylaxis or reactions likely to 
have been triggered or exacerbated by any component of the 
study drug;
• acute or chronic infectious disease other than hiV infection 
(included but not limited to viral hepatitis such as hepatitis 
B, active tuberculosis, active syphilis [i.e. currently treated], 
human T-cell lymphotropic virus [hTlV-1, hTlV-2]). Of note 
co-infection with hepatitis c was allowed as long as liver 
function parameters were within the following ranges: platelet 
>150.000/mm3; gamma-glutamyl transferase (γgT) ≤2·5 Uln; 
albumin >40 g/l and provided that participants were not 
receiving specific treatment during the study that could have 
interfered with the study objectives;
• acute, chronic or history of clinically relevant pulmonary, 
cardiovascular, gastrointestinal, hepatic, pancreatic or renal 
functional abnormality, encephalopathy, neuropathy or unstable 
central nervous system (cns) pathology, angina or cardiac 
arrhythmias, or any other clinically significant medical problems 
as determined by physical examination and/or laboratory 
screening tests and/or medical history;
• Uncontrolled dyslipidaemia;
• acute, chronic or history of immunodeficiency or autoimmune 
disease other than hiV infection; unstable asthma (defined 
as sudden acute attacks occurring for less than 3 hours without 
an obvious trigger, hospitalisation for asthma in the last 2 
years); food or wine induced asthma;
• history of malignancy unless there had been surgical excision 
that was considered to have achieved cure;
• active malignancy that may have required chemotherapy or 
radiation therapy;
• seizure disorder or any history of prior seizure;
• serious illness requiring systemic treatment and/or hospitalisa-
tion within 7 days prior to baseline;
• Pregnant or breastfeeding woman;
• active drug or alcohol abuse or dependence;
• Use of any investigational or non-registered product within 
3 months preceding baseline; and
• any condition, which in the opinion of the investigator, could 
have compromised the participant’s safety or adherence to 
the study protocol.
Appendix 2. Flow chart of study visits
 Screening  Days Treatment interruption – follow-up
Time Window ± 7 days  ± 2 days (except D25 ± 4) ± 2 days
Days (D) D-21 D0 D7 D14 D21 D25 D28 Twice weekly 
for 3 weeks 
Every week 
till VR
ART reintroduction 
visit
FU 
visit(s)***
informed consent X
check of in/eX criteria X X
Physical examination X X X X X X X X X X X
Body weight (kg) X X X X X X X X X X X
height measurement (cm) X
Medical history X
Telephone calls to 
participants
Day 3 
and 5 
serology for hBV, hcV, hiV X
haematology and 
biochemistry
X X X X X X X X X X*****
cD4 and cD8 count X X X X X X X X X X X
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 Screening  Days Treatment interruption – follow-up
Time Window ± 7 days  ± 2 days (except D25 ± 4) ± 2 days
Days (D) D-21 D0 D7 D14 D21 D25 D28 Twice weekly 
for 3 weeks 
Every week 
till VR
ART reintroduction 
visit
FU 
visit(s)***
Urinalysis X X X X X X X X**** X X
Blood pregnancy test X
Urine pregnancy test X X X X X X X X X
Vital signs X X X X X X X X X
ecg (12 lead) X X X X X
DrV/rTV or cOBi 
prescription
X X X X X X X X X
aBX464/placebo treatment 
dispensation and patient diary 
review 
X X X X X X
Blood samples–drug PK X* X* X* X* X**
Blood samples for viral load 
and mirna
X X X X X X X X X X X
hiV-1 genotyping X
leukapheresis (optional) X X
Blood samples for reservoir 
assessment
 • hiV-1 Dna
 • TilDa
X X X X
X
adverse events recording X X X X X X X X X
DrV: darunavir; rTV: ritonavir; cOBi: cobiscistat; FU: follow-up; Vr: viral rebound.
*: pre DrV/rTV or DrV/cOBi morning dose
**: pre DrV/rTV or DrV/cOBi morning dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 h post-dose (hospitalisation was not required)
***: every 14 days till undetectable viral load
****: urinalysis performed once a week
*****: only biochemistry required and for at least 28 days after treatment interruption
Appendix 3. Any treatment-emergent adverse events by system organ class and preferred term
50 mg ABX-464
(n=6)
150 mg ABX-464
(n=16)
Placebo
(n=8)
E n (%) E n(%) E n (%)
any treatment-emergent adverse events 10 4 (66.7%) 58 15 (93.8%) 13 3 (37.5%)
Blood and lymphatic system disorders 2 1 (16.7%) 0 0 0 0
 lymphadenopathy 2 1 (16.7%) 0 0 0 0
gastrointestinal disorders 2 1 (16.7%) 23 13 (81.3%) 1 1 (12.5%)
 abdominal pain 0 0 4 3 (18.8%) 0 0
 abdominal pain upper 0 0 5 4 (25.0%) 0 0
 Diarrhoea 2 1 (16.7%) 5 3 (18.8%) 0 0
 epigastric discomfort 0 0 1 1 (6.3%) 0 0
 gastric disorder 0 0 1 1 (6.3%) 0 0
 gastro-oesophageal reflux disease 0 0 1 1 (6.3%) 0 0
 nausea 0 0 2 2 (12.5%) 1 1 (12.5%)
 rectal haemorrhage 0 0 1 1 (6.3%) 0 0
 salivary gland disorder 0 0 1 1 (6.3%) 0 0
 Tooth infection 0 0 1 1 (6.3%) 0 0
 Toothache 0 0 1 1 (6.3%) 0 0
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50 mg ABX-464
(n=6)
150 mg ABX-464
(n=16)
Placebo
(n=8)
E n (%) E n(%) E n (%)
general disorders and administration site conditions 2 1 (16.7%) 10 6 (37.5%) 1 1 (12.5%)
 Fatigue 0 0 5 3 (18.8%) 0 0
 inflammation 1 1 (16.7%) 0 0 0 0
 influenza like illness 1 1 (16.7%) 1 1 (6.3%) 0 0
 Malaise 0 0 1 1 (6.3%) 0 0
 Oedema peripheral 0 0 2 1 (6.3%) 0 0
 Peripheral swelling 0 0 1 1 (6.3%) 0 0
 Pyrexia 0 0 0 0 1 1 (12.5%)
infections 0 0 3 3 (18.8%) 7 3 (37.5%)
 Bronchitis 0 0 0 0 1 1 (12.5%)
 eye infection 0 0 0 0 1 1 (12.5%)
 nasopharyngitis 0 0 0 0 2 2 (25.0%)
 Pharyngitis 0 0 0 0 1 1 (12.5%)
 rhinitis 0 0 1 1 (6.3%) 0 0
 sinusitis 0 0 1 1 (6.3%) 1 1 (12.5%)
 syphilis 0 0 0 0 1 1 (12.5%)
 Upper respiratory tract infection 0 0 1 1 (6.3%) 0 0
injury, poisoning and procedural complications 2 2 (33.3%) 0 0 0 0
 contusion 1 1 (16.7%) 0 0 0 0
 scar 1 1 (16.7%) 0 0 0 0
investigations 0 0 2 2 (12.5%) 1 1 (12.5%)
 activated partial thromboplastin time prolonged 0 0 1 1 (6.3%) 0 0
 c-reactive protein increased 0 0 1 1 (6.3%) 1 1 (12.5%)
Metabolism and nutrition disorders 0 0 1 1 (6.3%) 0 0
 gout 0 0 1 1 (6.3%) 0 0
Musculoskeletal and connective tissue disorders 0 0 10 8 (50.0%) 2 2 (25.0%)
 arthralgia 0 0 3 2 (12.5%) 1 1 (12.5%)
 Back pain 0 0 6 5 (31.3%) 0 0
 Myalgia 0 0 0 0 1 1 (12.5%)
 Pain in extremity 0 0 1 1 (6.3%) 0 0
nervous system disorders 2 2 (33.3%) 7 5 (31.3%) 0 0
 headache 2 2 (33.3%) 7 5 (31.3%) 0 0
Psychiatric disorders 0 0 1 1 (6.3%) 0 0
 insomnia 0 0 1 1 (6.3%) 0 0
renal and urinary disorders 0 0 1 1 (6.3%) 0 0
 Dysuria 0 0 1 1 (6.3%) 0 0
skin and subcutaneous tissue disorders 0 0 0 0 1 1 (12.5%)
 rash 0 0 0 0 1 1 (12.5%)
e: events; n: number of participants
Appendix 4. CD4 T cell count analysis (full analysis set)
CD4+ (cells/mm3) 50 mg ABX464
(total=6)
150 mg ABX464
(total=16)
Placebo
(total=8)
Difference in LS 
means: 150 mg vs 
placebo (95% CI)
P value
Day 0 n 6 16 8
Mean (sD) 1004.8 (201.7) 926.4 (394.6) 698.0 (179.8)
Median [range] 982.0 [800–1340] 784.5 [426–1792] 681.5 [448–998]
ls mean 926.4 698.0 228.4 (-78.1–534.8) 0.1365
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CD4+/CD8+ ratio 50 mg 
ABX-464
(total=6)
150 mg 
ABX-464
(total=16)
Placebo
(total=8)
Difference in LS 
means: 150 mg vs 
placebo (95% CI)
P value
Day 0 n 6 16 8
Mean (sD) 1.36 (0.64) 1.05 (0.38) 1.05 (0.270)
Median [range] 1.21 [0.7–2.2] 1.08 [0.5–1.8] 0.97 [0.7–1.6]
ls mean 1.05 1.05 0.00 (-0.31, 0.32) 0.9836
Day 7 n 6 16 7
Mean (sD) 1.29 (0.63) 0.94 (0.28) 1.03 (0.24)
Median [range] 1.23 [0.6–2.2] 0.92 [0.5–1.5] 1.03 [0.6–1.4]
ls mean 0.94 1.03 -0.09 (-0.34, 0.16) 0.4723
Day 14 n 5 15 7
Mean (sD) 1.18 (0.56) 1.08 (0.39) 1.16 (0.30)
Median [range] 1.03 [0.6–1.9] 1.10 [0.5–1.6] 0.99 [0.9–1.6]
ls mean 1.08 1.16 -0.08 (-0.42, 0.27) 0.6478
Day 21 n 6 15 8
Mean (sD) 1.30 (0.60) 1.04 (0.38) 1.20 (0.44)
Median [range] 1.27 [0.6–2.0] 1.10 [0.6–1.8] 1.08 [0.7–2.0]
ls mean 1.04 1.20 -0.16 (-0.52, 0.21) 0.3767
Day 25 n 3 9 6
Mean (sD) 1.53 (0.73) 1.11 (0.28) 1.15 (0.27)
Median [range] 1.88 [0.7–2.0] 1.09 [0.7–1.6] 1.10 [0.9–1.6]
ls mean 1.11 1.15 -0.04 (-0.36, 0.27) 0.7628
Day 28 n 6 13 7
Mean (sD) 1.39 (0.47) 1.06 (0.30) 1.08 (0.34)
Median [range] 1.48 [0.8–1.9] 1.05 [0.6–1.6] 0.97 [0.7–1.7]
ls mean 1.06 1.08 -0.03 (-0.33, 0.28) 0.8581
n: number of participants; sD: standard deviation; ls mean: least squares mean; ci: confidence interval.
Viral load analysed using an analysis of variance (anOVa) model with treatment as a fixed effect.
CD4+ (cells/mm3) 50 mg ABX464
(total=6)
150 mg ABX464
(total=16)
Placebo
(total=8)
Difference in LS 
means: 150 mg vs 
placebo (95% CI)
P value
Day 7 n 6 16 7
Mean (sD) 964.8 (258.8) 795.4 (268.8) 815.9 (387.8)
Median [range] 949.0 [630–1377] 758.0 [392–1290] 616.0 [527–1591]
ls mean 795.4 815.9 -20.4 (-310.3–269.4) 0.8849
Day 14 n 5 15 7
Mean (sD) 1119.0 (350.4) 846.6 (289.2) 786.4 (406.8)
Median [range] 970.0 [780–1571] 800.0 [506–1419] 575.0 [511–1628]
ls mean 846.6 786.4 60.2 (-253.9–374.2) 0.6937
Day 21 n 6 15 8
Mean (sD) 999.7 (358.0) 786.5 (293.5) 834.6 (368.8)
Median [range] 973.0 [520–1602] 740.0 [415–1337] 663.5 [547–1665]
ls mean 786.5 834.6 -48.2 (-340.0–243.7) 0.7349
Day 25 n 3 9 6
Mean (sD) 1089.7 (174.0) 942.1 (284.2) 816.7 (306.7)
Median [range] 1089.0 [916–1264] 926.0 [518–1487] 756.0 [401–1282]
ls mean 942.1 816.7 125.4 (-208.2–459.1) 0.4313
Day 28 n 6 13 6
Mean (sD) 987.2 (304.1) 853.4 (291.2) 838.2 (339.3)
Median [range] 864.5 [728–1516] 770.0 [494–1480] 688.0 [612–1491]
ls mean 853.4 838.2 15.2 (-303.5, 334.0) 0.9209
n: number of participants; sD: standard deviation; ls mean: least squares mean; ci: confidence interval.
Viral load analysed using an analysis of variance (anOVa) model with treatment as a fixed effect.
Appendix 5. CD4+/CD8+ T cell count ratio analysis (full analysis set)
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Appendix 6. Kaplan-Meier plot of time to virological rebound
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